Vertex is nearing an FDA decision that could become one of its more important strategic turning points since building its cystic fibrosis business. The company is seeking approval for povetacicept in IgA nephropathy, and BioSpace reported that analysts see the drug as a possible entry point into a multibillion-dollar kidney franchise and a broader revenue base beyond CF.

The timing matters because Vertex remains heavily concentrated in one therapeutic area. In the third quarter, the company posted $3.44 billion in revenue, with $3.27 billion coming from CF products. Trikafta contributed $2.44 billion, while Alyftrek added $706 million. By comparison, newer non-CF bets have been smaller so far: Journavx, approved in January 2025 for pain, brought in $58 million in the quarter, and Casgevy recorded $99 million.

The data

Povetacicept is under regulatory review for IgA nephropathy, with an FDA decision expected on or before Nov. 30. Vertex is seeking accelerated approval, which BioSpace said would allow the drug to be cleared on surrogate endpoints rather than direct proof of clinical improvement.

The filing is backed by phase 3 RAINIER data in more than 605 patients. In March, Vertex reported a 49.8% reduction in proteinuria at 36 weeks versus placebo. Proteinuria, or excess protein in the urine, is used in IgA nephropathy as an indicator of kidney damage and function.

The asset entered Vertex through its April 2024 acquisition of Alpine Immune Sciences for $4.9 billion, which BioSpace described as the biggest deal in Vertex’s history at the time. Alpine had previously reported mid-stage findings showing a 64.1% reduction in urine protein-to-creatinine ratio at 36 weeks in six treated patients. The company also had preclinical data supporting the APRIL/BAFF dual antagonist mechanism, targeting proteins involved in production of abnormal IgA molecules.

William Blair analyst Myles Minter told BioSpace the phase 3 results look “very strong” and are in the range of, if not slightly better than, currently approved therapies such as Otsuka’s Voyxact and Vera Therapeutics’ Trutakna. He added that the depth of proteinuria reduction could be predictive of stabilization of estimated glomerular filtration rate, which he said would support accelerated approval.

The commercial picture

The core industry signal is not only whether povetacicept reaches market, but whether it can begin to dilute Vertex’s dependence on CF. Minter told BioSpace there is a real path to a multibillion-dollar product, while Evan Seigerman of BMO Capital Markets said the company is looking for its next key franchise beyond CF after investors had hoped that pain or sickle cell disease might fill that role.

BMO has been especially bullish. In a May 4 note cited by BioSpace, the firm said an approval could herald an evolution of Vertex “that may be nothing short of iconic.” That framing reflects the scale of the gap Vertex still needs to close between its established CF engine and its newer assets.

Povetacicept may also carry broader franchise value than a single kidney indication. BioSpace reported that Vertex is studying the drug in generalized myasthenia gravis and primary membranous nephropathy. Minter said that gives the asset pipeline-in-a-product potential, even if he does not expect it to match the eventual size of the CF business.

The road here

Vertex’s first FDA approval came in 2011 with Incivek for hepatitis C, but that product was later pulled from the market in 2014 after competitors moved in. The company’s trajectory changed with Kalydeco in 2012, the first drug to treat the underlying cause of cystic fibrosis, followed by four more CF medicines.

According to BioSpace, when Reshma Kewalramani became CEO in 2020 after serving as chief medical officer under Jeffrey Leiden, part of her mandate was to build growth that was not solely reliant on CF. That strategy has included internal development, which produced Journavx, and external dealmaking, which brought Alpine and povetacicept into the company.

An approval would not by itself resolve Vertex’s concentration risk, but it would give the company a more credible second franchise path than its recent launches have yet delivered.